XML 50 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborations (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 01, 2018
USD ($)
item
Mar. 31, 2018
item
Mar. 31, 2016
USD ($)
item
Mar. 31, 2015
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jan. 01, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborations                      
Collaboration revenue         $ 41,439 $ 5,890   $ 42,393 $ 11,730    
Current portion of deferred revenue         5,139     5,139   $ 4,478 $ 5,373
Roche                      
Collaborations                      
Achieved milestone payment received which will be recognized over period of performance             $ 1,800        
Collaboration | Roche                      
Collaborations                      
Reversal of cumulative milestone revenue not occur for developmental milestone         10,000            
Cumulative catch-up of revenue for developmental milestone recognized         1,200            
Remaining amount to be recognized over research and development period         8,800            
Cumulative Non-refundable milestone payments received                     $ 2,000
Initial cash payment     $ 45,000                
Collaboration revenue               6,700      
Cstone Agreement                      
Collaborations                      
Eligible milestone payments $ 346,000                    
Licensed product term from first commercial sale 12 years                    
Number of potential collaboration programs | item 3                    
Number of option rights to obtain exclusive license | item 3                    
Number of collaboration programs with exclusive commercialization rights for licensed products | item 3                    
Number of material promises | item 6                    
Number of performance obligation | item 1                    
Non-refundable upfront payment received $ 40,000                    
Cstone Agreement | Development and regulatory milestones                      
Collaborations                      
Eligible milestone payments 118,500                    
Cstone Agreement | Sales-based milestones                      
Collaborations                      
Eligible milestone payments $ 227,500                    
Cstone Agreement | C Stone                      
Collaborations                      
Number of materials components | item 2                    
Initial cash payment $ 40,000                    
Collaboration revenue         40,000            
Deferred revenue         0     0      
Roche Agreement                      
Collaborations                      
Number of potential collaboration programs | item     5                
Number of collaboration programs with agreed upon targets | item     2                
Non-refundable upfront payment received     $ 45,000                
Total eligible contingent option fees and milestone payments     965,000                
Eligible option fees and milestones prior to licensing for all potential collaboration programs     $ 215,000                
Deferred revenue         $ 1,200     $ 1,200      
Research and development services, performance period         8 years     8 years      
Roche Agreement | Exercise Of License Right Option                      
Collaborations                      
Number of collaboration programs with specified commercial rights for each party | item     2                
Roche Agreement | Roche                      
Collaborations                      
Number of option rights to obtain exclusive license | item     5                
Number of performance obligation | item   1                  
Deferred revenue         $ 48,300     $ 48,300      
Current portion of deferred revenue         5,200     $ 5,200      
Achieved milestone payment received which will be recognized over period of performance         $ 10,000            
Roche Agreement | Roche | Prior To Exercise License Right Option                      
Collaborations                      
Written termination notice period     120 days                
Roche Agreement | Roche | Exercise Of License Right Option                      
Collaborations                      
Number of collaboration programs with exclusive commercialization rights for licensed products | item     3                
Roche Agreement | Roche | Exercise Of License Option Product Not Commercially Sold                      
Collaborations                      
Written termination notice period     120 days                
Roche Agreement | Roche | Exercise Of License Option Product Commercially Sold                      
Collaborations                      
Written termination notice period     180 days                
Alexion                      
Collaborations                      
Non-refundable upfront and milestone payment received       $ 18,800              
Non-refundable upfront payment received       15,000              
Non-refundable milestone payment received       $ 3,800              
Collaborative partner's funding responsibility of research and development costs incurred under the research plan (as a percent)       100.00%              
Number of deliverables | item     3                
Reimbursable research and development costs recognized           3,100     5,900    
Non-substantive milestone payment previously       $ 1,800              
Alexion | Calculated under Revenue Guidance in Effect before Topic 606                      
Collaborations                      
Collaboration revenue           $ 4,500     $ 8,900